{"id":390086,"date":"2021-03-08T00:00:00","date_gmt":"2021-03-08T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0001-2020-biopharma-alzheimers-disease-disease-landscape-and-forecast-g7-2020\/"},"modified":"2026-04-27T23:36:12","modified_gmt":"2026-04-27T23:36:12","slug":"dlsfcg0001-2020-biopharma-alzheimers-disease-disease-landscape-and-forecast-g7-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0001-2020-biopharma-alzheimers-disease-disease-landscape-and-forecast-g7-2020\/","title":{"rendered":"Alzheimer&#8217;s Disease | Disease Landscape and Forecast | G7 | 2020"},"content":{"rendered":"<p>The Alzheimer\u2019s disease (AD) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide open the opportunity for more-effective alternatives\u2014in particular, disease-modifying therapies (DMTs) that can slow the course of the disease. In response, drug developers\u2014from big pharma to small biotech\u2014continue to invest heavily in disease-modifying approaches owing to the tremendous clinical and commercial opportunity in this arena, despite decades of late-phase failures. Although many uncertainties remain about the launch prospects for late-phase anti-amyloid MAbs from Biogen, Eisai, and Roche, key opinion leaders (KOLs) have expressed cautious optimism about these agents and the numerous anti-tau therapies in early- to mid-phase trials. Meanwhile, hope remains for late-phase therapies from Lundbeck\/Otsuka, Otsuka\/Avanir, and Axsome that are in development for key AD agitation, a key neuropsychiatric symptom. Ultimately, however, the launch of any of these agents is far from guaranteed.<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<ul>\n<li>What are the drivers and constraints in the AD market?<\/li>\n<li>How large is the treatable AD population by key segments?<\/li>\n<li>What clinical and commercial impact can be expected from DMTs and neurospsychiatric therapies, should they launch? Which populations will be most affected?<\/li>\n<li>What are experts\u2019 opinions of the launch prospects for agents in development?<\/li>\n<\/ul>\n<p>PRODUCT DESCRIPTION<\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p>Solution Enhancement<\/p>\n<p><em>Disease Landscape &#038; Forecast <\/em>will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.<\/p>\n","protected":false},"template":"","class_list":["post-390086","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-alzheimers-disease","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390086","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390086\/revisions"}],"predecessor-version":[{"id":576438,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390086\/revisions\/576438"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390086"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}